By Alex Philippidis, GEN Edge|2023-01-06T12:05:24-08:00December 27, 2022|

Like its namesake star twinkling 25 light-years from Earth, Vega Therapeutics hopes to shine as brightly in treating rare blood disorders, starting with a therapy for von Willebrand disease (VWD) that the company plans ...

By Kyle LaHucik, Endpoints|2022-12-12T14:48:25-08:00December 6, 2022|

Biotech incubator Star Therapeutics has launched another galaxy-themed drug developer, which next year will test a new antibody in a bleeding disorder currently treated by Takeda’s Vonvendi. Star lined up a who’s who of ...

By Gwendolyn Wu, Biopharma Dive|2022-12-12T09:40:48-08:00December 6, 2022|

Vega Therapeutics is the second company to emerge from Star’s “hub-and-spoke” model following the February launch of Electra Therapeutics. The latest company in Star Therapeutics’ universe of biotech offshoots debuted on Tuesday with plans ...

By Cormac Sheridan, Bioworld|2022-12-13T09:04:51-08:00December 6, 2022|

Vega Therapeutics Inc. emerged from stealth in advance of a podium presentation at this year’s American Society of Hematology (ASH) meeting in New Orleans. The company, a spin-out from Star Therapeutics Inc., will disclose ...